Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10316754 | 0.79 | POLB (0.41) | POLBALDH1A1TDP1MCL1CYP1A2 | |
| SCHEMBL15865874 | 0.74 | POLB (0.41) | POLBALDH1A1TDP1MCL1CYP1A2 | |
| SCHEMBL14879723 | 0.70 | POLB (0.40) | POLBALDH1A1TDP1MCL1CYP1A2 | |
| SCHEMBL30536564 | 0.67 | ALDH1A1 (0.39) | POLBALDH1A1TDP1MCL1 | |
| SCHEMBL104614 | 0.66 | — | — | |
| SCHEMBL10894987 | 0.66 | TRIM24 (0.42) | ALDH1A1 | |
| SCHEMBL9716444 | 0.64 | POLB (0.39) | POLBALDH1A1TDP1MCL1 | |
| SCHEMBL20608593 | 0.64 | ALDH1A1 (0.40) | POLBALDH1A1TDP1MCL1LMNA | |
| SCHEMBL14879721 | 0.64 | ALDH1A1 (0.40) | POLBALDH1A1TDP1MCL1LMNA | |
| SCHEMBL30379423 | 0.63 | POLB (0.45) | POLBALDH1A1TDP1MCL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658806-B2 | Process for preparing optically active antrocin | DEYEW BIOTECH CORP. (TW) | 2014-02-25 | — | — | US | disclosed |
| US-8658806-B2 | Process for preparing optically active antrocin | DEYEW BIOTECH CORP. (TW) | 2014-02-25 | — | — | US | disclosed |
| US-20130096324-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE ANTROCIN | DEYEW BIOTECH CORP. (TW) | 2013-04-18 | — | — | US | disclosed |
| US-20130096324-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE ANTROCIN | DEYEW BIOTECH CORP. (TW) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096324-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE ANTROCIN | KTN1, TMSB10, TSN | POLB 3914/4885ALDH1A1 3568/4885TDP1 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.